Can Keflex Treat Proteus mirabilis?
Yes, Keflex (cephalexin) can treat Proteus mirabilis infections, as it is FDA-approved and demonstrates in vitro activity against this organism, but it should be reserved for uncomplicated urinary tract infections in specific clinical contexts rather than as a first-line agent for all P. mirabilis infections.
FDA-Approved Activity
The FDA drug label explicitly states that cephalexin is "active against most strains" of Proteus mirabilis both in vitro and in clinical infections 1. The drug is specifically indicated for:
- Genitourinary tract infections (including acute prostatitis) caused by P. mirabilis 1
- Bone infections caused by P. mirabilis 1
Clinical Context and Limitations
When Cephalexin IS Appropriate:
For uncomplicated UTIs in infants >28 days old, cephalexin (50-100 mg/kg/day in 4 doses) is listed as an acceptable oral option 2. This represents a specific niche where first-generation cephalosporins maintain utility.
For simple UTIs with confirmed susceptibility, cephalexin can be effective. Studies demonstrate that P. mirabilis isolates from UTIs show susceptibility to cephalexin, with mean MICs of 5.7 ± 3.0 mcg/mL 3. Clinical trials show cephalexin achieves adequate urinary concentrations even in patients with impaired renal function 4.
When Cephalexin Should NOT Be Used:
First-generation cephalosporins like cephalexin are explicitly NOT recommended for Lyme disease 5, and this principle extends to their limited spectrum against many resistant organisms.
For complicated intra-abdominal infections, cephalexin is inadequate—guidelines recommend broader agents like third-generation cephalosporins or carbapenems 6.
For pyelonephritis, oral β-lactams (including cephalexin) are "less effective than other available agents" and require an initial IV dose of ceftriaxone or aminoglycoside if used at all 7.
Critical Resistance Considerations
The emergence of multidrug-resistant P. mirabilis is alarming, particularly in catheter-associated UTIs where resistance rates are significantly higher 8. Recent data from Egypt shows:
- 80.6% resistance to trimethoprim-sulfamethoxazole
- 57.3% resistance to amoxicillin-clavulanic acid
- 55.3% resistance to ceftazidime
- 37.9% ESBL-producing isolates 8
While this data is from Egypt, it highlights the global trend toward resistance that makes empiric use of first-generation cephalosporins increasingly problematic.
Practical Algorithm for Use
Confirm the infection source: Cephalexin is appropriate for uncomplicated UTIs, not for complicated infections or systemic disease
Check susceptibility testing: Culture and sensitivity should guide therapy 1. Do not use cephalexin empirically if local resistance patterns are unknown
Consider patient factors:
Dosing: 500 mg orally 3-4 times daily for adults 9; 50-100 mg/kg/day in 4 doses for children 2
Common Pitfalls
Do not use cephalexin for empiric treatment of complicated UTIs or pyelonephritis—it lacks adequate gram-negative coverage compared to fluoroquinolones or third-generation cephalosporins 7
Do not assume susceptibility—P. mirabilis resistance to first-generation cephalosporins is increasing, particularly in healthcare-associated infections 8
Avoid in patients with recent antibiotic exposure—prior antibiotic use within 4-6 weeks increases resistance risk 10